111 related articles for article (PubMed ID: 24636075)
1. Obligatory information that a patient diagnosed of prostate cancer and candidate for an active surveillance protocol must know.
Rubio-Briones J; Iborra I; Ramírez M; Calatrava A; Collado A; Casanova J; Domínguez-Escrig J; Gómez-Ferrer A; Ricós JV; Monrós JL; Dumont R; López-Guerrero JA; Salas D; Solsona E
Actas Urol Esp; 2014 Nov; 38(9):559-65. PubMed ID: 24636075
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
3. Active surveillance in low-risk prostate cancer. Patient acceptance and results.
Hernández V; Blázquez C; de la Peña E; Pérez-Fernández E; Díaz FJ; Llorente C
Actas Urol Esp; 2013 Oct; 37(9):533-7. PubMed ID: 23618513
[TBL] [Abstract][Full Text] [Related]
4. Analysis of expanded criteria to select candidates for active surveillance of low-risk prostate cancer.
Jo JK; Lee HS; Lee YI; Lee SE; Hong SK
Asian J Androl; 2015; 17(2):248-52. PubMed ID: 25432498
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer.
Rubio-Briones J; Borque A; Esteban LM; Iborra I; López PA; Gil JM; Pallás Y; Fumadó L; Martínez-Breijo S; Chantada V; Gómez E; Quicios C; Congregado CB; Medina R; Ortiz M; Montesino M; Clar F; Soto J; Campá JM
Actas Urol Esp; 2016; 40(1):3-10. PubMed ID: 26115777
[TBL] [Abstract][Full Text] [Related]
6. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
7. Does cumulative prostate cancer length (CCL) in prostate biopsies improve prediction of clinically insignificant cancer at radical prostatectomy in patients eligible for active surveillance?
Chen DJ; Falzarano SM; McKenney JK; Przybycin CG; Reynolds JP; Roma A; Jones JS; Stephenson A; Klein E; Magi-Galluzzi C
BJU Int; 2015 Aug; 116(2):220-9. PubMed ID: 25060664
[TBL] [Abstract][Full Text] [Related]
8. Predictive criteria of insignificant prostate cancer: what is the correspondence of linear extent to percentage of cancer in a single core?
Billis A; Quintal MM; Freitas LL; Costa LB; Ferreira U
Int Braz J Urol; 2015; 41(2):367-72. PubMed ID: 26005981
[TBL] [Abstract][Full Text] [Related]
9. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
10. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
11. Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.
Overholser S; Nielsen M; Torkko K; Cwilka D; Weaver B; Shi X; Leach RJ; Hernandez J; Huang T; Thompson IM; Thompson IM
J Urol; 2015 Sep; 194(3):680-4. PubMed ID: 25636657
[TBL] [Abstract][Full Text] [Related]
12. Pathologic findings in radical prostatectomy specimens from patients eligible for active surveillance with highly selective criteria: a multicenter study.
Beauval JB; Ploussard G; Soulié M; Pfister C; Van Agt S; Vincendeau S; Larue S; Rigaud J; Gaschignard N; Rouprêt M; Drouin S; Peyromaure M; Long JA; Iborra F; Vallancien G; Rozet F; Salomon L;
Urology; 2012 Sep; 80(3):656-60. PubMed ID: 22770616
[TBL] [Abstract][Full Text] [Related]
13. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
[TBL] [Abstract][Full Text] [Related]
14. Tumor lesion diameter on diffusion weighted magnetic resonance imaging could help predict insignificant prostate cancer in patients eligible for active surveillance: preliminary analysis.
Lee DH; Koo KC; Lee SH; Rha KH; Choi YD; Hong SJ; Chung BH
J Urol; 2013 Oct; 190(4):1213-7. PubMed ID: 23727188
[TBL] [Abstract][Full Text] [Related]
15. [The significance of PSA density as predictive factor in Afro-Caribbean patients eligible for active surveillance by the French protocol criteria].
Loiselle A; Senechal C; Nevoux P; Benazzouz H; Bhakkan-Mambir B; Casenave J; Gourtaud G; Fofana M; Blanchet P
Prog Urol; 2014 May; 24(6):327-33. PubMed ID: 24821554
[TBL] [Abstract][Full Text] [Related]
16. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
17. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
Wong LM; Tang V; Peters J; Costello A; Corcoran N
BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
[TBL] [Abstract][Full Text] [Related]
18. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of men with screen-detected prostate cancer eligible for active surveillance who were managed expectantly.
van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
Eur Urol; 2009 Jan; 55(1):1-8. PubMed ID: 18805628
[TBL] [Abstract][Full Text] [Related]
20. The contemporary concept of significant versus insignificant prostate cancer.
Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
